An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The first stage of this study will evaluates the tolerability of different concentrations of Conbercept eye drop to patients with corneal neovascularization.

The second stage of this study will evaluate the effectiveness of conbercept eye drop initially.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chengdu Kanghong Biotech Co., Ltd.
• Treatments: Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Signed the informed consent form, volunteered to participate in the trial and followed up according to the protocol.

• Ages from 18 to 75,male or female.

• Superficial or deep neovascularization induced by trauma/chemical burn/inflammation/corneal transplantation.

Exclusion Criteria:

• Subjects who had significant defect in the corneal epithelium.

• Study eye had been injected of anti-vegf drugs within 3 months before screening

• Study eye was performed surgery (except keratoplasty) within 3 months prior screening, or eye surgery was planned during this trial period.

• Oral glucocorticoid administration within 1 month prior screening (except for duration less than 7 days)

• Systemic use of anti-vegf drugs within 45 days prior to screening.

• Have history of abnormal coagulation, such as end-stage liver disease, or are taking anticoagulants（except aspirin）.

• Uncontrolled clinical problems such as canner etc..

• Unable or unwilling to use effective contraception.

• Positive blood tests for pregnancy (female subjects)

• Participated in drug clinical trials within 3 months before the first administration.

• The researchers think the participants were not suitable for this trail.